CLAIM STATUS

1. (allowed) A method for treating a neoplasm comprising cells, comprising:

administering to said neoplasm an amount of a mutant human herpes simplex virus which is oncolytic to cells in said neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparan sulfate..

2. (allowed) A method of claim 1, wherein said virus comprises a deletion in the UL44 gene which codes for heparan binding of glycoprotein C polypeptide

3. (allowed) A method of claim 1, wherein said virus comprises a deletion of amino acids 33-123 in the UL44 gene.

4. (allowed) A method of claim1, wherein said virus comprises an insertion in the UL44 gene which codes for heparan binding of glycoprotein C polypeptide

5. (allowed) A method of claim 1, wherein the parental strain of said virus is KOS.

6. (allowed) A method of claim 1, wherein said virus is gC-39.

7. (allowed) A method of claim 1, wherein said virus is impaired in its ability to infect, or attach to the surface of normal cells as compared to the wild-type parental strain.

8. (allowed) A method of claim 1, wherein said virus is impaired in its ability to infect neuronal cells as compared to the wild-type parental strain.

9. (allowed) A method of claim 1, wherein said neoplasm is an adenocarcinoma.

10. (allowed) A kit comprising a mutant human herpes simplex virus which is oncolytic to cells in a neoplasm, wherein said virus does not produce a functionally active wild-type glycoprotein C polypeptide capable of binding heparan sulfate and a chemotheraputic agent.

11. (cancelled).

12. (cancelled).

13. (cancelled).